TauRx’s deliver Alzheimer’s disease therapy results
Company’s hydromethylthionine mesylate therapy reduced neurodegeneration during pivotal trial
Read More
Tag: hydromethylthionine mesylate
- Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb
- Kainova expands DT 7012 trial into Europe
- Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
- CatalYm begins phase 2b trial of visugromab in second-line liver cancer treatment
- FDA approves new high dose Spinraza regimen for SMA
